Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
5,800
Employees5,800
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
5,800
Employees5,800

MRNA Key Statistics

Market cap
13.58B
Market cap13.58B
Price-Earnings ratio
-3.79
Price-Earnings ratio-3.79
Dividend yield
Dividend yield
Average volume
11.51M
Average volume11.51M
High today
$34.58
High today$34.58
Low today
$33.52
Low today$33.52
Open price
$32.55
Open price$32.55
Volume
319.99K
Volume319.99K
52 Week high
$170.47
52 Week high$170.47
52 Week low
$29.25
52 Week low$29.25

MRNA News

Sherwood News 19h
German court rules Pfizer violated Moderna Covid vaccine patent, sending Moderna even higher

German court rules Pfizer violated Moderna Covid vaccine patent, sending Moderna even higher Moderna shares are rising after a German court handed the vaccine...

German court rules Pfizer violated Moderna Covid vaccine patent, sending Moderna even higher
Seeking Alpha 20h
Moderna aims 2027 approval for Merck-partnered cancer shot

Moderna (NASDAQ:MRNA) is targeting market approval of a personalized vaccine the company is developing with Merck (NYSE:MRK) for skin cancer in 2027, one of its...

Moderna aims 2027 approval for Merck-partnered cancer shot
Sherwood News 22h
Moderna rises after $6 million in insider purchases revealed

Moderna rises after $6 million in insider purchases revealed Moderna ’ s share price is spiking after the company disclosed early Wednesday that CEO Stephane B...

Moderna rises after $6 million in insider purchases revealed

Analyst ratings

63%

of 27 ratings
Buy
22.2%
Hold
63%
Sell
14.8%

More MRNA News

TipRanks 24h
Moderna Stock Climbs as CEO and Director Make Strategic Insider Purchases

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic insider stock purchases by the CEO and di...

Simply Wall St 5d
Moderna (NasdaqGS:MRNA) Drops 13% Following Weak 2024 Earnings Outlook

recently announced a significant decrease in fourth-quarter revenue and profits for 2024, alongside setting a conservative revenue projection for 2025. The comp...

Moderna (NasdaqGS:MRNA) Drops 13% Following Weak 2024 Earnings Outlook
TipRanks 6d
Moderna receives MHRA marketing authorization for RSV vaccine

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for mRESVIA, indicated for a...

Quartz 7d
Trump administration may cancel Moderna's bird flu vaccine

According to Bloomberg News, a $590 million contract awarded to Modern by the U.S. government to aid in vaccine development for bird flu is being reevaluated....

Trump administration may cancel Moderna's bird flu vaccine
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.